UNSPSC 51373457: Codeine/promethazine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373457 Codeine/promethazine, a Commodity code, nominally addresses a specific pharmaceutical product, but recent state and local solicitation activity under this code shows a mismatch with the code's narrow scope. The two recent opportunities tagged to this code — Seminole County's procurement of naloxone and drug deactivation systems and the Minnesota Multistate Cooperative Purchasing Alliance's (MMCAP) RFP for generic multi-source pharmaceuticals and OTC products — are both substantially broader pharmaceutical and medical-supply acquisitions rather than codeine/promethazine–specific purchases. The Seminole County opportunity (IFB 60459723LAS, due July 26, 2023) sought annual supplies of naloxone units and safe drug deactivation systems through competitive bidding for community health initiatives. The MMCAP RFP (S1070000015802, due March 26, 2026) established statewide cooperative contracts for generic pharmaceuticals and OTC products across participating state and local government facilities, requiring vendors to supply through authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act certifications.

The code shows recent activity in Florida and Minnesota, with MMCAP's cooperative purchasing vehicle extending to Oregon and other participating states. Issuing bodies include county health departments and state cooperative purchasing alliances operating on behalf of distributed state and local members. The mismatch between the code's nominal scope (codeine/promethazine) and the actual procurement activity (broader naloxone, multi-source generics, and OTC products) suggests that this Commodity code may not accurately reflect how state and local procurement offices are classifying pharmaceutical acquisitions, or that the code is being applied to larger pharmaceutical family-level procurements rather than single-product buys. Vendors pursuing opportunities under this code should verify the actual product or therapeutic category being solicited rather than relying on the code designation alone.